← Back to Search

Monoclonal Antibodies

BMS-986463 for Advanced Cancer

Phase 1
Recruiting
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1
Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre-treatment biopsy must be obtained
Must not have
Participants must not have Leptomeningeal metastases
Participants must not have concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial is testing the safety and effectiveness of increasing amounts of BMS-986463 in patients with certain advanced cancers."

Who is the study for?
This trial is for individuals with certain advanced cancers, including uterine, ovarian, non-small cell lung cancer, and serous cystadenocarcinoma. Participants should be able to receive escalating doses of the study drug.
What is being tested?
The focus of this study is on BMS-986463. It's given in increasing amounts to see how safe it is and how well it works against specific advanced cancers.
What are the potential side effects?
While not specified here, side effects typically range from mild reactions at the injection site to more serious issues affecting organs or blood cells; specifics will depend on individual responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I have a tumor that can be biopsied in addition to the main one.
Select...
My cancer cannot be removed by surgery and has spread.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have cancer spread to the lining of my brain and spinal cord.
Select...
I have no other cancers needing treatment or active cancers in the last 2 years.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2: Dose ExpansionExperimental Treatment1 Intervention
Group II: Arm 1: Dose EscalationExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,686 Previous Clinical Trials
4,129,621 Total Patients Enrolled
~160 spots leftby Dec 2028
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top